{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T23:00:22Z","timestamp":1774393222989,"version":"3.50.1"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2008,7,8]],"date-time":"2008-07-08T00:00:00Z","timestamp":1215475200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1038\/ncponc1179","type":"journal-article","created":{"date-parts":[[2008,7,8]],"date-time":"2008-07-08T11:39:26Z","timestamp":1215517166000},"page":"531-542","source":"Crossref","is-referenced-by-count":142,"title":["The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2"],"prefix":"10.1038","volume":"5","author":[{"given":"Aleix","family":"Prat","sequence":"first","affiliation":[]},{"given":"Jos\u00e9","family":"Baselga","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2008,7,8]]},"reference":[{"key":"BFncponc1179_CR1","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","volume":"56","author":"A Jemal","year":"2006","unstructured":"Jemal A et al. (2006) Cancer Statistics, 2006. CA Cancer J Clin 56: 106\u2013130","journal-title":"CA Cancer J Clin"},{"key":"BFncponc1179_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/annonc\/mdl498","volume":"18","author":"J Ferlay","year":"2007","unstructured":"Ferlay J et al. (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581\u2013592","journal-title":"Ann Oncol"},{"key":"BFncponc1179_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1200\/JCO.2003.03.088","volume":"21","author":"CI Li","year":"2003","unstructured":"Li CI et al. (2003) Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 21: 28\u201334","journal-title":"J Clin Oncol"},{"key":"BFncponc1179_CR4","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.2005.10.036","volume":"23","author":"CK Osborne","year":"2005","unstructured":"Osborne CK et al. (2005) Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 23: 1616\u20131622","journal-title":"J Clin Oncol"},{"key":"BFncponc1179_CR5","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687\u20131717","DOI":"10.1016\/S0140-6736(05)66544-0"},{"key":"BFncponc1179_CR6","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1056\/NEJMoa040331","volume":"350","author":"RC Coombes","year":"2004","unstructured":"Coombes RC et al. (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081\u20131092","journal-title":"N Engl J Med"},{"key":"BFncponc1179_CR7","doi-asserted-by":"crossref","unstructured":"The Breast International Group 1-98 Collaborative Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353: 2747\u20132757","DOI":"10.1056\/NEJMoa052258"},{"key":"BFncponc1179_CR8","doi-asserted-by":"crossref","unstructured":"ATAC Trialists' Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365: 60\u201362","DOI":"10.1016\/S0140-6736(04)17666-6"},{"key":"BFncponc1179_CR9","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","volume":"366","author":"R Jakesz","year":"2005","unstructured":"Jakesz R et al. (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366: 455\u2013462","journal-title":"Lancet"},{"key":"BFncponc1179_CR10","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1023\/A:1013128213451","volume":"12","author":"W Eiermann","year":"2001","unstructured":"Eiermann W et al. (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12: 1527\u20131532","journal-title":"Ann Oncol"},{"key":"BFncponc1179_CR11","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1200\/JCO.2005.04.005","volume":"23","author":"IE Smith","year":"2005","unstructured":"Smith IE et al. (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) Multicenter double-blind randomized trial. J Clin Oncol 23: 5108\u20135116","journal-title":"J Clin Oncol"},{"key":"BFncponc1179_CR12","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1002\/cncr.21872","volume":"106","author":"L Cataliotti","year":"2006","unstructured":"Cataliotti L et al. (2006) Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer. Cancer 106: 2095\u20132103","journal-title":"Cancer"},{"key":"BFncponc1179_CR13","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1200\/JCO.2000.18.22.3748","volume":"18","author":"J Bonneterre","year":"2000","unstructured":"Bonneterre J et al. (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 18: 3748\u20133757","journal-title":"J Clin Oncol"},{"key":"BFncponc1179_CR14","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","volume":"18","author":"JM Nabholtz","year":"2000","unstructured":"Nabholtz JM et al. (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 18: 3758\u20133767","journal-title":"J Clin Oncol"},{"key":"BFncponc1179_CR15","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1200\/JCO.2001.19.10.2596","volume":"19","author":"H Mouridsen","year":"2001","unstructured":"Mouridsen H et al. (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596\u20132606","journal-title":"J Clin Oncol"},{"key":"BFncponc1179_CR16","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1200\/JCO.2003.04.194","volume":"21","author":"H Mouridsen","year":"2003","unstructured":"Mouridsen H et al. (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21: 2101\u20132109","journal-title":"J Clin Oncol"},{"key":"BFncponc1179_CR17","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1093\/annonc\/mdg362","volume":"14","author":"R Paridaens","year":"2003","unstructured":"Paridaens R et al. (2003) Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14: 1391\u20131398","journal-title":"Ann Oncol"},{"key":"BFncponc1179_CR18","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1200\/JCO.2002.10.057","volume":"20","author":"A Howell","year":"2002","unstructured":"Howell A et al. (2002) Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20: 3396\u20133403","journal-title":"J Clin Oncol"},{"key":"BFncponc1179_CR19","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1200\/JCO.2002.10.058","volume":"20","author":"CK Osborne","year":"2002","unstructured":"Osborne CK et al. (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20: 3386\u20133395","journal-title":"J Clin Oncol"},{"key":"BFncponc1179_CR20","unstructured":"Kaufman B et al. (2006) Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2 positive, hormone-dependent metastatic breast cancer (MBC) [abstract #LBA2]. European Society for Medical Oncology (ESMO) Congress: 2006 29 September to 3 October; Istanbul, Turkey"},{"key":"BFncponc1179_CR21","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1677\/erc.1.00776","volume":"11","author":"A Ring","year":"2004","unstructured":"Ring A et al. (2004) Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11: 643\u2013658","journal-title":"Endocr Relat Cancer"},{"key":"BFncponc1179_CR22","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1158\/1078-0432.CCR-06-2540","volume":"13","author":"S Massarweh","year":"2007","unstructured":"Massarweh S et al. (2007) Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res 13: 1950\u20131954","journal-title":"Clin Cancer Res"},{"key":"BFncponc1179_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrc721","volume":"2","author":"S Ali","year":"2002","unstructured":"Ali S et al. (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2: 101\u2013112","journal-title":"Nat Rev Cancer"},{"key":"BFncponc1179_CR24","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1002\/j.1460-2075.1993.tb05756.x","volume":"12","author":"S Ali","year":"1993","unstructured":"Ali S et al. (1993) Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A\/B region. EMBO J 12: 1153\u20131160","journal-title":"EMBO J"},{"key":"BFncponc1179_CR25","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/jnci\/djh166","volume":"96","author":"J Shou","year":"2004","unstructured":"Shou J et al. (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2\/neu crosstalk in ER\/HER2-positive breast cancer. J Natl Cancer Inst 96: 926\u2013935","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc1179_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden Y et al. (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127\u2013137","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFncponc1179_CR27","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrc1609","volume":"5","author":"NE Hynes","year":"2005","unstructured":"Hynes NE and Lane HA (2005) ErbB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341\u2013354","journal-title":"Nat Rev Cancer"},{"key":"BFncponc1179_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/BF01961241","volume":"24","author":"C Benz","year":"1992","unstructured":"Benz C et al. (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2\/neu. Breast Cancer Res Treat 24: 85\u201395","journal-title":"Breast Cancer Res Treat"},{"key":"BFncponc1179_CR29","first-page":"2435","volume":"10","author":"R Pietras","year":"1995","unstructured":"Pietras R et al. (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435\u20132446","journal-title":"Oncogene"},{"key":"BFncponc1179_CR30","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1126\/science.1105396","volume":"306","author":"J Schlessinger","year":"2004","unstructured":"Schlessinger J (2004) Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 306: 1506\u20131507","journal-title":"Science"},{"key":"BFncponc1179_CR31","doi-asserted-by":"publisher","first-page":"7159","DOI":"10.1073\/pnas.84.20.7159","volume":"84","author":"RM Hudziak","year":"1987","unstructured":"Hudziak RM et al. (1987) Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 84: 7159\u20137163","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncponc1179_CR32","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ et al. (1989) Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707\u2013712","journal-title":"Science"},{"key":"BFncponc1179_CR33","doi-asserted-by":"publisher","first-page":"6115","DOI":"10.1038\/sj.onc.1203972","volume":"11","author":"D Yu","year":"2000","unstructured":"Yu D et al. (2000) Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 11: 6115\u20136121","journal-title":"Oncogene"},{"key":"BFncponc1179_CR34","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","volume":"89","author":"P Carter","year":"1992","unstructured":"Carter P et al. (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285\u20134289","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncponc1179_CR35","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/bjc.1996.259","volume":"73","author":"Y Tokuda","year":"1996","unstructured":"Tokuda Y et al. (1996) In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. Br J Cancer 73: 1362\u20131365","journal-title":"Br J Cancer"},{"key":"BFncponc1179_CR36","first-page":"2825","volume":"58","author":"J Baselga","year":"1998","unstructured":"Baselga J et al. (1998) Recombinant humanized anti-HER2 antibody (HerceptinTM) enhances the antitumor activity of paclitaxel and doxorubicin against HER2\/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825\u20132831","journal-title":"Cancer Res"},{"key":"BFncponc1179_CR37","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S0093-7754(01)90276-3","volume":"28","author":"J Baselga","year":"2001","unstructured":"Baselga J et al. (2001) Mechanism of action of trastuzumab and scientific update. Semin Oncol 28: 4\u201311","journal-title":"Semin Oncol"},{"key":"BFncponc1179_CR38","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783\u2013792","journal-title":"N Engl J Med"},{"key":"BFncponc1179_CR39","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","volume":"23","author":"M Marty","year":"2005","unstructured":"Marty M et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 Study Group. J Clin Oncol 23: 4265\u20134274","journal-title":"J Clin Oncol"},{"key":"BFncponc1179_CR40","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673\u20131684","journal-title":"N Engl J Med"},{"key":"BFncponc1179_CR41","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659\u20131672","journal-title":"N Engl J Med"},{"key":"BFncponc1179_CR42","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa053028","volume":"354","author":"H Joensuu","year":"2006","unstructured":"Joensuu H et al. (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354: 809\u2013820","journal-title":"N Engl J Med"},{"key":"BFncponc1179_CR43","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0140-6736(06)67951-8","volume":"367","author":"I Smith","year":"2006","unstructured":"Smith I (2006) Trastuzumab for early breast cancer. Lancet 367: 107","journal-title":"Lancet"},{"key":"BFncponc1179_CR44","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733\u20132743","journal-title":"N Engl J Med"},{"key":"BFncponc1179_CR45","volume-title":"Proc Am Soc Clin Oncol: 2007 1\u20135 June; Chicago, IL","author":"J Baselga","year":"2007","unstructured":"Baselga J et al. (2007) Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T [abstract #1004]. Proc Am Soc Clin Oncol: 2007 1\u20135 June; Chicago, IL"},{"key":"BFncponc1179_CR46","volume-title":"Proc Am Soc Clin Oncol: 2007 1\u20135 June; Chicago, IL","author":"M Beeram","year":"2007","unstructured":"Beeram M et al. (2007) A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC) [abstract #1042]. Proc Am Soc Clin Oncol: 2007 1\u20135 June; Chicago, IL"},{"key":"BFncponc1179_CR47","volume-title":"Proc Am Soc Clin Oncol: 2007 June 1\u20135; Chicago, IL","author":"S Modi","year":"2006","unstructured":"Modi S et al. (2006) Phase I trial of KOS-953, a heat shock protein 90 inhibitor, and trastuzumab (T) [abstract #501]. Proc Am Soc Clin Oncol: 2007 June 1\u20135; Chicago, IL"},{"key":"BFncponc1179_CR48","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1535-6108(04)00083-2","volume":"5","author":"MC Franklin","year":"2004","unstructured":"Franklin MC et al. (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5: 317\u2013328","journal-title":"Cancer Cell"},{"key":"BFncponc1179_CR49","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1126\/science.1241159","volume":"189","author":"S Remillard","year":"1975","unstructured":"Remillard S et al. (1975) Antimitotic activity of the potent tumor inhibitor maytansine. Science 189: 1002\u20131005","journal-title":"Science"},{"key":"BFncponc1179_CR50","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc1716","volume":"5","author":"L Whitesell","year":"2005","unstructured":"Whitesell L et al. (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5: 761\u2013772","journal-title":"Nat Rev Cancer"},{"key":"BFncponc1179_CR51","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1200\/JCO.2000.18.17.3172","volume":"18","author":"CK Osborne","year":"2000","unstructured":"Osborne CK et al. (2000) Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 18: 3172\u20133186","journal-title":"J Clin Oncol"},{"key":"BFncponc1179_CR52","first-page":"4338s","volume":"7","author":"C Osborne","year":"2001","unstructured":"Osborne C et al. (2001) Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 7: 4338s\u20134342s","journal-title":"Clin Cancer Res"},{"key":"BFncponc1179_CR53","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0960-0760(00)00108-4","volume":"74","author":"PJ Kushner","year":"2000","unstructured":"Kushner PJ et al. (2000) Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74: 311\u2013317","journal-title":"J Steroid Biochem Mol Biol"},{"key":"BFncponc1179_CR54","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1677\/erc.0.0060373","volume":"6","author":"RI Nicholson","year":"1999","unstructured":"Nicholson RI et al. (1999) Involvement of steroid hormone and growth factor crosstalk in endocrine response in breast cancer. Endocr Relat Cancer 6: 373\u2013387","journal-title":"Endocr Relat Cancer"},{"key":"BFncponc1179_CR55","first-page":"4429s","volume":"7","author":"A Lee","year":"2001","unstructured":"Lee A et al. (2001) Crosstalk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res 7: 4429s\u20134435s","journal-title":"Clin Cancer Res"},{"key":"BFncponc1179_CR56","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/jcb.10168","volume":"85","author":"M Wilson","year":"2002","unstructured":"Wilson M et al. (2002) Identification and characterization of a negative regulatory element within the epidermal growth factor receptor gene first intron in hormone-dependent breast cancer cells. J Cell Biochem 85: 601\u2013614","journal-title":"J Cell Biochem"},{"key":"BFncponc1179_CR57","first-page":"6624","volume":"52","author":"K Russell","year":"1992","unstructured":"Russell K et al. (1992) Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. Cancer Res 52: 6624\u20136629","journal-title":"Cancer Res"},{"key":"BFncponc1179_CR58","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1210\/en.2003-0567","volume":"144","author":"J Frasor","year":"2003","unstructured":"Frasor J et al. (2003) Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144: 4562\u20134574","journal-title":"Endocrinology"},{"key":"BFncponc1179_CR59","first-page":"321","volume":"20","author":"NJ McKenna","year":"1999","unstructured":"McKenna NJ et al. (1999) Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20: 321\u2013344","journal-title":"Endocr Rev"},{"key":"BFncponc1179_CR60","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00018-003-3222-5","volume":"61","author":"C Barnes","year":"2004","unstructured":"Barnes C et al. (2004) Novel estrogen receptor coregulators and signaling molecules in human diseases. Cell Mol Life Sci 61: 281\u2013291","journal-title":"Cell Mol Life Sci"},{"key":"BFncponc1179_CR61","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/jcb.20566","volume":"96","author":"R Singh","year":"2005","unstructured":"Singh R et al. (2005) Steroid hormone receptor signaling in tumorigenesis. J Cell Biochem 96: 490\u2013505","journal-title":"J Cell Biochem"},{"key":"BFncponc1179_CR62","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1210\/er.2003-0023","volume":"25","author":"CL Smith","year":"2004","unstructured":"Smith CL et al. (2004) Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25: 45\u201371","journal-title":"Endocr Rev"},{"key":"BFncponc1179_CR63","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1126\/science.277.5328.965","volume":"277","author":"SL Anzick","year":"1997","unstructured":"Anzick SL et al. (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277: 965\u2013968","journal-title":"Science"},{"key":"BFncponc1179_CR64","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/jnci\/95.5.353","volume":"95","author":"CK Osborne","year":"2003","unstructured":"Osborne CK et al. (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2\/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95: 353\u2013361","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc1179_CR65","doi-asserted-by":"publisher","first-page":"8517","DOI":"10.1073\/pnas.91.18.8517","volume":"91","author":"S Aronica","year":"1994","unstructured":"Aronica S et al. (1994) Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci USA 91: 8517\u20138521","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncponc1179_CR66","doi-asserted-by":"publisher","first-page":"18447","DOI":"10.1074\/jbc.M910345199","volume":"275","author":"S Kahlert","year":"2000","unstructured":"Kahlert S et al. (2000) Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem 275: 18447\u201318453","journal-title":"J Biol Chem"},{"key":"BFncponc1179_CR67","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/35035131","volume":"407","author":"T Simoncini","year":"2000","unstructured":"Simoncini T et al. (2000) Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407: 538\u2013541","journal-title":"Nature"},{"key":"BFncponc1179_CR68","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1038\/sj.onc.1206436","volume":"26","author":"C Morelli","year":"2003","unstructured":"Morelli C et al. (2003) Estrogen receptor-alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells. Oncogene 26: 4007\u20134016","journal-title":"Oncogene"},{"key":"BFncponc1179_CR69","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1749-6632.2002.tb04109.x","volume":"963","author":"A Migliaccio","year":"2002","unstructured":"Migliaccio A et al. (2002) Src is an initial target of sex steroid hormone action. Ann NY Acad Sci 963: 185\u2013190","journal-title":"Ann NY Acad Sci"},{"key":"BFncponc1179_CR70","doi-asserted-by":"crossref","first-page":"A4000","DOI":"10.1200\/jco.2007.25.18_suppl.4000","volume":"25","author":"E Van Cutsem","year":"2007","unstructured":"Van Cutsem E et al. (2007) Randomized phase III study of irinotecan and 5-FU\/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial [abstract]. J Clin Oncol 25: A4000","journal-title":"J Clin Oncol"},{"key":"BFncponc1179_CR71","first-page":"116","volume":"16","author":"RX Song","year":"2002","unstructured":"Song RX et al. (2002) Linkage of rapid estrogen action to MAPK activation by ER\u03b1-Shc association and Shc pathway activation. Mol Endocrinol 16: 116\u2013127","journal-title":"Mol Endocrinol"},{"key":"BFncponc1179_CR72","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0960-0760(01)00072-3","volume":"78","author":"J MacGregor Schafer","year":"2001","unstructured":"MacGregor Schafer J et al. (2001) Estrogen receptor \u03b1 mediated induction of the transforming growth factor \u03b1 gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells. J Steroid Biochem Mol Biol 78: 41\u201350","journal-title":"J Steroid Biochem Mol Biol"},{"key":"BFncponc1179_CR73","doi-asserted-by":"publisher","first-page":"5041","DOI":"10.1128\/MCB.20.14.5041-5047.2000","volume":"20","author":"J Font de Mora","year":"2000","unstructured":"Font de Mora J et al. (2000) AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20: 5041\u20135047","journal-title":"Mol Cell Biol"},{"key":"BFncponc1179_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1023\/A:1005798224288","volume":"42","author":"L Witters","year":"1997","unstructured":"Witters L et al. (1997) Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat 42: 1\u20135","journal-title":"Breast Cancer Res Treat"},{"key":"BFncponc1179_CR75","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1200\/JCO.2005.01.172","volume":"23","author":"MC Gutierrez","year":"2005","unstructured":"Gutierrez MC et al. (2005) Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23: 2469\u20132476","journal-title":"J Clin Oncol"},{"key":"BFncponc1179_CR76","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1200\/JCO.2001.19.18.3808","volume":"19","author":"MJ Ellis","year":"2001","unstructured":"Ellis MJ et al. (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and\/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19: 3808\u20133816","journal-title":"J Clin Oncol"},{"key":"BFncponc1179_CR77","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/nrc1211","volume":"3","author":"S Johnston","year":"2003","unstructured":"Johnston S et al. (2003) Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 3: 821\u2013831","journal-title":"Nat Rev Cancer"},{"key":"BFncponc1179_CR78","doi-asserted-by":"publisher","first-page":"8266","DOI":"10.1158\/0008-5472.CAN-05-4045","volume":"66","author":"S Massarweh","year":"2006","unstructured":"Massarweh S et al. (2006) Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2\/neu-positive breast cancer. Cancer Res 66: 8266\u20138273","journal-title":"Cancer Res"},{"key":"BFncponc1179_CR79","first-page":"5887","volume":"60","author":"H Kurokawa","year":"2000","unstructured":"Kurokawa H et al. (2000) Inhibition of HER2\/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60: 5887\u20135894","journal-title":"Cancer Res"},{"key":"BFncponc1179_CR80","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/bjc.1992.22","volume":"65","author":"C Wright","year":"1992","unstructured":"Wright C et al. (1992) Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65: 118\u2013121","journal-title":"Br J Cancer"},{"key":"BFncponc1179_CR81","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0378-1119(94)00534-Y","volume":"159","author":"E Berns","year":"1995","unstructured":"Berns E et al. (1995) Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 159: 11\u201318","journal-title":"Gene"},{"key":"BFncponc1179_CR82","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1038\/sj.bjc.6690196","volume":"79","author":"S Houston","year":"1999","unstructured":"Houston S et al. (1999) Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 79: 1220\u20131226","journal-title":"Br J Cancer"},{"key":"BFncponc1179_CR83","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1200\/JCO.2003.09.098","volume":"21","author":"A Lipton","year":"2003","unstructured":"Lipton A et al. (2003) Serum HER-2\/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 21: 1967\u20131972","journal-title":"J Clin Oncol"},{"key":"BFncponc1179_CR84","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1200\/JCO.2002.20.6.1467","volume":"20","author":"A Lipton","year":"2002","unstructured":"Lipton A et al. (2002) Elevated serum HER-2\/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20: 1467\u20131472","journal-title":"J Clin Oncol"},{"key":"BFncponc1179_CR85","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1200\/JCO.2005.07.559","volume":"23","author":"M Dowsett","year":"2005","unstructured":"Dowsett M et al. (2005) Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer\u2014a study from the IMPACT Trialists. J Clin Oncol 23: 2477\u20132492","journal-title":"J Clin Oncol"},{"key":"BFncponc1179_CR86","unstructured":"Viale G et al. (2005) Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer [abstract #44]. In Proceedings of the San Antonio Breast Cancer Symposium: 9 December 2005, San Antonio, TX"},{"key":"BFncponc1179_CR87","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1200\/JCO.2005.04.3034","volume":"24","author":"MJ Ellis","year":"2006","unstructured":"Ellis MJ et al. (2006) Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 24: 3019\u20133025","journal-title":"J Clin Oncol"},{"key":"BFncponc1179_CR88","unstructured":"Dowsett M et al. (2006) Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial [abstract #48]. In Proceedings of the San Antonio Breast Cancer Symposium: 2006 December 14\u201317; San Antonio, TX"},{"key":"BFncponc1179_CR89","first-page":"3804","volume":"57","author":"J Daly","year":"1997","unstructured":"Daly J et al. (1997) Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells. Cancer Res 57: 3804\u20133811","journal-title":"Cancer Res"},{"key":"BFncponc1179_CR90","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1200\/JCO.2001.19.14.3357","volume":"19","author":"A Buzdar","year":"2001","unstructured":"Buzdar A et al. (2001) Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 19: 3357\u20133366","journal-title":"J Clin Oncol"},{"key":"BFncponc1179_CR91","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.0.CO;2-5","volume":"83","author":"A Buzdar","year":"1998","unstructured":"Buzdar A et al. (1998) Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 83: 1142\u20131152","journal-title":"Cancer"},{"key":"BFncponc1179_CR92","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1200\/JCO.2000.18.7.1399","volume":"18","author":"M Kaufmann","year":"2000","unstructured":"Kaufmann M et al. (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 18: 1399\u20131411","journal-title":"J Clin Oncol"},{"key":"BFncponc1179_CR93","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10549-006-9307-8","volume":"102","author":"PK Marcom","year":"2007","unstructured":"Marcom PK et al. (2007) The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 102: 43\u201349","journal-title":"Breast Cancer Res Treat"},{"key":"BFncponc1179_CR94","unstructured":"Kaufman B et al. (2006) Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer [abstract #a3]. In Proceedings of the San Antonio Breast Cancer Symposium: 2006 December 14\u201317; San Antonio, TX"},{"key":"BFncponc1179_CR95","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/jnci\/djk151","volume":"99","author":"G Arpino","year":"2007","unstructured":"Arpino G et al. (2007) Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 99: 694\u2013705","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc1179_CR96","doi-asserted-by":"publisher","first-page":"7795","DOI":"10.1073\/pnas.0602468103","volume":"103","author":"W Xia","year":"2006","unstructured":"Xia W et al. (2006) A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA 103: 7795\u20137800","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncponc1179_CR97","doi-asserted-by":"publisher","first-page":"S145","DOI":"10.1677\/erc.1.00992","volume":"12","author":"SR Johnston","year":"2005","unstructured":"Johnston SR (2005) Clinical trials of intracellular signal transductions inhibitors for breast cancer\u2014a strategy to overcome endocrine resistance. Endocr Relat Cancer 12: S145\u2013S157","journal-title":"Endocr Relat Cancer"},{"key":"BFncponc1179_CR98","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1634\/theoncologist.9-suppl_3-20","volume":"9","author":"M Ellis","year":"2004","unstructured":"Ellis M (2004) Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist 9: 20\u201326","journal-title":"Oncologist"},{"key":"BFncponc1179_CR99","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jsbmb.2007.05.019","volume":"106","author":"SR Johnston","year":"2007","unstructured":"Johnston SR et al. (2007) Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer. J Steroid Biochem Mol Biol 106: 180\u2013186","journal-title":"J Steroid Biochem Mol Biol"},{"key":"BFncponc1179_CR100","first-page":"707","volume":"1","author":"AS Clark","year":"2002","unstructured":"Clark AS et al. (2002) Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1: 707\u2013717","journal-title":"Mol Cancer Ther"},{"key":"BFncponc1179_CR101","first-page":"A5168","volume":"45","author":"S Pancholi","year":"2004","unstructured":"Pancholi S et al. (2004) Elevated levels of Akt and p90rsk provide tamoxifen-resistant MCF-7 cells with a survival advantage involving Bad and Bcl-2 [abstract]. Proc Am Assoc Cancer Res 45: A5168","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BFncponc1179_CR102","doi-asserted-by":"crossref","unstructured":"Baselga J et al. (2004) Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results [abstract #544]. Proc Am Soc Clin Oncol 23","DOI":"10.1200\/jco.2004.22.90140.544"},{"key":"BFncponc1179_CR103","unstructured":"Tabernero J et al. (2005) A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor everolimus (RAD001) in patients (pts) with advanced solid tumors [abstract #3007]. Proc Am Soc Clin Oncol 23"},{"key":"BFncponc1179_CR104","doi-asserted-by":"crossref","unstructured":"Carpenter JT et al. (2005) Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer [abstract # 564]. Proc Am Soc Clin Oncol 23","DOI":"10.1200\/jco.2005.23.16_suppl.564"},{"key":"BFncponc1179_CR105","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O'Reilly","year":"2006","unstructured":"O'Reilly KE et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500\u20131508","journal-title":"Cancer Res"},{"key":"BFncponc1179_CR106","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis CA (2007) Trastuzumab\u2014mechanism of action and use in clinical practice. N Engl J Med 357: 39\u201351","journal-title":"N Engl J Med"},{"key":"BFncponc1179_CR107","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","volume":"20","author":"CL Vogel","year":"2002","unstructured":"Vogel CL et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719\u2013726","journal-title":"J Clin Oncol"},{"key":"BFncponc1179_CR108","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1200\/JCO.2003.02.018","volume":"21","author":"HJ Burstein","year":"2003","unstructured":"Burstein HJ et al. (2003) Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21: 2889\u20132895","journal-title":"J Clin Oncol"},{"key":"BFncponc1179_CR109","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1200\/JCO.2005.04.1764","volume":"24","author":"N Robert","year":"2006","unstructured":"Robert N et al. (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24: 2786\u20132792","journal-title":"J Clin Oncol"}],"container-title":["Nature Clinical Practice Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncponc1179.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc1179","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc1179.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:53:09Z","timestamp":1684443189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncponc1179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,8]]},"references-count":109,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["BFncponc1179"],"URL":"https:\/\/doi.org\/10.1038\/ncponc1179","relation":{},"ISSN":["1743-4254","1743-4262"],"issn-type":[{"value":"1743-4254","type":"print"},{"value":"1743-4262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,8]]}}}